PDF Publication Title:
Text from PDF Page: 009
Published OnlineFirst June 6, 2017; DOI: 10.1158/1541-7786.MCR-17-0164 for the anti-PSMA-IR700 might be successful new treatment modality for prostate cancer especially at diagnosis, initial treat- ment and at the time of locoregional recurrence in the pelvis. Disclosure of Potential Conflicts of Interest No potential conflict of interest were disclosed. Authors' Contributions Conception and design: T. Nagaya, P.L. Choyke, H. Kobayashi Development of methodology: H. Kobayashi Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T. Nagaya, Y. Nakamura, S. Okuyama, F. Ogata, H. Kobayashi Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T. Nagaya, S. Okuyama, Y. Maruoka, P.L. Choyke, H. Kobayashi References 1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7–30. 2. Klein EA, Kupelian PA. Localized prostate cancer: radiation or surgery? Urol Clin North Am 2003;30:315–30. 3. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002;2:389–96. 4. Gulley J, Dahut WL. Chemotherapy for prostate cancer: finally an advance! Am J Ther 2004;11:288–94. 5. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20. 6. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45. 7. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal anti- body. Clin Cancer Res 1996;2:1289–97. 8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42. 9. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548–51. 10. Barinka C, Sacha P, Sklenar J, Man P, Bezouska K, Slusher BS, et al. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 2004;13:1627–35. 11. Chen Y, Chatterjee S, Lisok A, Minn I, Pullambhatla M, Wharram B, et al. A PSMA-targeted theranostic agent for photodynamic therapy. J Photochem Photobiol B 2016;167:111–6. 12. Huang X, Bennett M, Thorpe PE. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate- specific membrane antigen. Prostate 2004;61:1–11. 13. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927–35. 14. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82:2256–61. 15. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807–11. 16. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637–40. 17. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen- deprivation therapy. Urology 1996;48:326–34. 18. Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 2008;53:R61–109. 19. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy target- ing specific membrane molecules. Nat Med 2011;17:1685–91. www.aacrjournals.org Near-Infrared Photoimmunotherapy Targeting PSMA Writing, review, and/or revision of the manuscript: T. Nagaya, P.L. Choyke, H. Kobayashi Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): P.L. Choyke, H. Kobayashi Study supervision: P.L. Choyke, H. Kobayashi Grant Support All authors were supported by the Intramural Research Program of the NIH, NCI, Center for Cancer Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Received March 27, 2017; revised May 3, 2017; accepted June 1, 2017; published OnlineFirst June 6, 2017. 20. Ogawa M, Tomita Y, Nakamura Y, Lee MJ, Lee S, Tomita S, et al. Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget 2017; 8:10425–36. 21. Hanaoka H, Nakajima T, Sato K, Watanabe R, Phung Y, Gao W, et al. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. Nanomedicine 2015;10:1139–47. 22. Nagaya T, Nakamura Y, Sato K, Harada T, Choyke PL, Hodge JW, et al. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget 2017;8:8807–17. 23. Nagaya T, Nakamura Y, Sato K, Harada T, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy of B-cell lymphoma. Mol Oncol 2016; 10:1404–14. 24. Nagaya T, Nakamura Y, Sato K, Zhang YF, Ni M, Choyke PL, et al. Near infrared photoimmunotherapy with an anti-mesothelin antibody. Onco- target 2016;7:23361–9. 25. Sato K, Choyke PL, Kobayashi H. Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a mouse model. PLoS One 2014;9:e113276. 26. Watanabe R, Hanaoka H, Sato K, Nagaya T, Harada T, Mitsunaga M, et al. Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies? J Nucl Med 2015;56:140–4. 27. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, et al. Potent antitumor activity of an auristatin-conjugated, fully human mono- clonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006;12:2591–6. 28. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies con- firm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192–8. 29. Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 2009;69:1128–41. 30. Kahn D, Williams RD, Seldin DW, Libertino JA, Hirschhorn M, Dreicer R, et al. Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152: 1490–5. 31. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57:3629–34. 32. Troyer JK, Beckett ML, Wright GL Jr. Location of prostate-specific mem- brane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997; 30:232–42. 33. Wong WW, Schild SE, Vora SA, Ezzell GA, Nguyen BD, Ram PC, et al. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. Int J Radiat Oncol Biol Phys 2011;81:e423–9. 34. Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of Mol Cancer Res; 15(9) September 2017 1161 Downloaded from mcr.aacrjournals.org on December 1, 2020. © 2017 American Association for Cancer Research.PDF Image | Near-Infrared Photoimmunotherapy Targeting Prostate Cancer
PDF Search Title:
Near-Infrared Photoimmunotherapy Targeting Prostate CancerOriginal File Name Searched:
near-ir-photoimmunotherapy-prostate-cancer.pdfDIY PDF Search: Google It | Yahoo | Bing
Cruise Ship Reviews | Luxury Resort | Jet | Yacht | and Travel Tech More Info
Cruising Review Topics and Articles More Info
Software based on Filemaker for the travel industry More Info
The Burgenstock Resort: Reviews on CruisingReview website... More Info
Resort Reviews: World Class resorts... More Info
The Riffelalp Resort: Reviews on CruisingReview website... More Info
| CONTACT TEL: 608-238-6001 Email: greg@cruisingreview.com | RSS | AMP |